?

Discussions and Knowledge Gaps

1

Does germline ATRX loss-of-function confer a clinically meaningful tumor predisposition (e.g., osteosarcoma) in ATR-X syndrome, and if so, through which mechanism (ALT/telomere instability, heterochromatin/genome-integrity failure, or a sporadic association)?

KNOWLEDGE GAP OPEN gap_atrx_osteosarcoma_tumor_predisposition

Attached to

pathophysiology#ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin

Somatic ATRX loss is a recurrent driver of the alternative lengthening of telomeres (ALT) phenotype across multiple cancers, and GeneReviews notes that osteosarcoma has been reported in a few males with germline ATRX pathogenic variants. It remains unclear whether germline ATRX loss-of- function meaningfully predisposes to osteosarcoma or other tumors in ATR-X syndrome, and whether any such risk is mediated by the same heterochromatin/ genome-integrity functions captured by the ATRX/DAXX node. The entry does not assert a tumor-predisposition phenotype because the association is rare and the germline mechanism is unestablished.

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Osteosarcoma has been reported in"

GeneReviews documents that osteosarcoma has been reported in a few males with germline ATRX pathogenic variants, motivating this open question about tumor predisposition in ATR-X syndrome.

⚙

Pathophysiology

5

ATRX Chromatin Remodeler Loss of Function

ATR-X syndrome is caused by hemizygous loss-of-function variants in ATRX (Xq21.1), which encodes a member of the SWI2/SNF2 family of ATP-dependent chromatin-remodeling proteins. ATRX carries an ADD (ATRX-DNMT3-DNMT3L) plant-homeodomain-like zinc finger that reads the H3K9me3 heterochromatin mark and a SNF2-type helicase/ATPase domain. Diverse missense and truncating mutations disrupt either chromatin targeting or remodeling activity, leading to a "global transcriptional regulator" defect that dysregulates many genes, including the alpha-globin genes, which explains the multisystem ATR-X phenotype.

neuron CL:0000540

chromatin remodeling GO:0006338 ↓ DECREASED regulation of DNA-templated transcription GO:0006355 ⚠ ABNORMAL

Downstream

ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin Loss of ATRX chromatin-remodeling function destabilizes the ATRX-DAXX complex and impairs H3.3 deposition at heterochromatic regions.

Tandem-Repeat Binding and Allele-Specific Gene Dysregulation Loss of ATRX disrupts its binding to G-rich tandem repeats, causing allele-specific gene dysregulation including alpha-globin downregulation.

Impaired Sertoli Cell Survival and Androgen Signaling ATRX loss in the Sertoli cell lineage causes cell-cycle arrest, apoptosis, and impaired androgen receptor co-activation.

Impaired Oligodendrocyte Differentiation and CNS Myelination ATRX loss impairs oligodendrocyte progenitor differentiation along the oligodendrocyte lineage, producing CNS myelination deficits.

Intellectual Disability

Global Developmental Delay

Hypotonia

Distinctive Craniofacial Features

Telecanthus

Everted Lower Lip

Microcephaly

Seizures

Feeding Difficulties

Drooling

Skeletal Anomalies

Gastrointestinal Anomalies

Show evidence (2 references)

PMID:7697714 SUPPORT Human Clinical

"We have shown that ATR-X results from diverse mutations of XH2, a member of a subgroup of the helicase superfamily that includes proteins involved in a wide range of cellular functions, including DNA recombination and repair (RAD16, RAD54, and ERCC6) and regulation of transcription (SW12/SNF2,..."

The original Gibbons et al. report identified ATRX (XH2) as a SWI2/SNF2-family helicase whose mutation causes ATR-X syndrome, establishing the chromatin- regulation defect.

PMID:7697714 SUPPORT Human Clinical

"The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."

Directly supports the model that loss of ATRX function dysregulates many genes, including alpha-globin, producing the multisystem phenotype.

ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin

ATRX partners with the histone chaperone DAXX to deposit the replication-independent histone variant H3.3 at heterochromatic and repetitive genomic regions (pericentromeric heterochromatin, telomeres, and tandem repeats), maintaining the H3K9me3 silencing mark. ATRX localizes to promyelocytic leukemia (PML) nuclear bodies as part of this complex. Loss of ATRX destabilizes the ATRX-DAXX complex and impairs heterochromatin maintenance and proper silencing of repetitive elements.

neuron CL:0000540

heterochromatin organization GO:0070828 ↓ DECREASED nucleosome assembly GO:0006334 ↓ DECREASED

Downstream

Tandem-Repeat Binding and Allele-Specific Gene Dysregulation Impaired ATRX/DAXX-mediated heterochromatin maintenance at tandem-repeat regions is the mechanistic bridge to allele-specific dysregulation of genes embedded in those repeats.

Show evidence (4 references)

PMID:12953102 SUPPORT In Vitro

"Taken together, the results suggest that ATRX functions in conjunction with Daxx in a novel chromatin-remodeling complex. The defects in ATRX syndrome may result from inappropriate expression of genes controlled by this complex."

Establishes the ATRX-DAXX chromatin-remodeling complex and links its dysfunction to the gene-expression defects of ATR-X syndrome.

PMID:12953102 SUPPORT In Vitro

"a proportion of ATRX and Daxx colocalize in promyelocytic leukemia nuclear bodies, with which Daxx had previously been located"

Documents ATRX/DAXX colocalization in PML nuclear bodies, part of the complex's heterochromatin-associated localization.

PMID:26773061 SUPPORT Other

"We provide an overview of the individual components (ATRX, DAXX and/or H3.3) tested in each study and propose a model where the ATRX/DAXX chaperone complex deposits H3.3 to maintain the H3K9me3 modification at heterochromatin throughout the genome."

Reviews the mechanistic model that the ATRX/DAXX chaperone deposits H3.3 to maintain the H3K9me3 heterochromatin mark genome-wide.

+ 1 more reference

Tandem-Repeat Binding and Allele-Specific Gene Dysregulation

ATRX binds G-rich tandem-repeat (TR) sequences in telomeres and euchromatin, including sequences predicted to form non-B DNA structures such as G-quadruplexes. When ATRX is mutated, genes associated with these TRs are dysregulated in a size-dependent manner, producing skewed allelic expression. This mechanism accounts for the variable phenotypes seen with identical ATRX mutations and the down-regulation of alpha-globin, which is embedded in a TR-rich subtelomeric region.

erythroid lineage cell CL:0000764 neuron CL:0000540

regulation of DNA-templated transcription GO:0006355 ⚠ ABNORMAL

Downstream

Alpha-Thalassemia with HbH Hemoglobin

Show evidence (2 references)

PMID:21029860 SUPPORT In Vitro

"Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression."

Demonstrates ATRX binding to tandem-repeat sequences and size-dependent dysregulation of associated genes when ATRX is mutated.

PMID:21029860 SUPPORT In Vitro

"Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro, suggesting a mechanism by which ATRX may play a role in various nuclear processes and how this is perturbed when ATRX is mutated."

Supports the G-quadruplex/non-B DNA binding mechanism underlying ATRX's role at repetitive regions and its perturbation in disease.

Impaired Sertoli Cell Survival and Androgen Signaling

ATRX is required in the supporting (Sertoli) cell lineage of the developing testis. In a Sertoli-cell-specific Atrx knockout mouse, proliferating Sertoli cells undergo a prolonged G2/M phase and apoptosis during fetal life, producing small testes and spermatogenesis defects. ATRX physically interacts with the androgen receptor (AR) and co-activates AR target genes, providing a tissue-specific mechanism for the genital and urogenital anomalies (hypospadias, undescended testes, ambiguous genitalia) of ATR-X syndrome.

Sertoli cell CL:0000216

regulation of DNA-templated transcription GO:0006355 ⚠ ABNORMAL

Downstream

Ambiguous Genitalia

Hypospadias

Cryptorchidism

Show evidence (2 references)

PMID:21427128 SUPPORT Model Organism

"ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."

Mouse model shows that Sertoli-cell-specific Atrx loss causes the cellular basis (cell-cycle arrest and apoptosis) for testicular hypoplasia.

PMID:21427128 SUPPORT Model Organism

"These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR."

Links ATRX to androgen-receptor-dependent transcription, a mechanism for the genital/urogenital anomalies seen in ATR-X syndrome.

Impaired Oligodendrocyte Differentiation and CNS Myelination

ATRX promotes oligodendrocyte progenitor cell (OPC) differentiation along the oligodendrocyte lineage and suppresses astrogliogenesis. In male mice, loss of ATRX causes CNS myelination deficits, with OPCs failing to differentiate and instead acquiring a more plastic state favoring astrocytic differentiation. ATRX also acts systemically via thyroxine to regulate the onset of myelination. These functions provide a mechanism for the white matter pathology observed in ATR-X syndrome patients.

oligodendrocyte precursor cell CL:0002453 oligodendrocyte CL:0000128

oligodendrocyte differentiation GO:0048709 ↓ DECREASED myelination GO:0042552 ↓ DECREASED

Downstream

Abnormal CNS Myelination

Show evidence (2 references)

PMID:37925436 SUPPORT Model Organism

"We show that loss of ATRX leads to myelination deficits in male mice that are partially rectified upon systemic thyroxine administration."

Mouse model demonstrates that ATRX loss causes CNS myelination deficits, providing a mechanism for white matter pathology in ATR-X syndrome.

PMID:37925436 SUPPORT Model Organism

"OPCs lacking ATRX fail to differentiate along the oligodendrocyte lineage and acquire a more plastic state that favors astrocytic differentiation in vitro and in vivo."

Demonstrates the OPC-intrinsic role of ATRX in promoting oligodendrocyte differentiation and suppressing astrogliogenesis.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Digestive 2

Feeding Difficulties Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"gastrointestinal manifestations and feeding difficulties, excessive drooling"

GeneReviews documents gastrointestinal manifestations and feeding difficulties.

Gastrointestinal Anomalies Abnormality of the gastrointestinal tract HP:0011024

Show evidence (1 reference)

PMID:36292677 SUPPORT Human Clinical

"with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features"

Cohort study lists gastrointestinal anomalies among the characteristic features of ATR-X syndrome, consistent with the GeneReviews note on GI manifestations.

Genitourinary 2

Hypospadias Hypospadias HP:0000047

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia"

GeneReviews lists hypospadias as a genital anomaly in ATR-X syndrome.

Cryptorchidism Cryptorchidism HP:0000028

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"a range from hypospadias and undescended testicles"

GeneReviews documents undescended testicles among genital anomalies.

Head and Neck 3

Distinctive Craniofacial Features VERY_FREQUENT Abnormal facial shape HP:0001999

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."

GeneReviews details the characteristic craniofacial features of ATR-X syndrome.

Microcephaly Microcephaly HP:0000252

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Craniofacial abnormalities include small head circumference"

GeneReviews documents small head circumference (microcephaly) among the craniofacial abnormalities.

Drooling Drooling HP:0002307

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"

GeneReviews lists excessive drooling among manifestations to manage.

Musculoskeletal 2

Hypotonia VERY_FREQUENT Hypotonia HP:0001252

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay"

GeneReviews lists hypotonia among the characterizing features.

Skeletal Anomalies Abnormality of the skeletal system HP:0000924

Show evidence (1 reference)

PMID:36292677 SUPPORT Human Clinical

"A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."

Cohort study lists skeletal anomalies among the characteristic features of ATR-X syndrome.

Nervous System 3

Intellectual Disability VERY_FREQUENT Intellectual disability HP:0001249

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."

GeneReviews lists intellectual disability as a core characteristic of the syndrome.

Global Developmental Delay VERY_FREQUENT Global developmental delay HP:0001263

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"mild-to-profound developmental delay / intellectual disability (DD/ID)"

GeneReviews documents developmental delay as a defining feature.

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."

GeneReviews lists seizures among the manifestations requiring management.

Other 5

Telecanthus Telecanthus HP:0000506

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"telecanthus or widely spaced eyes, short triangular nose, tented upper lip"

GeneReviews lists telecanthus as a craniofacial feature.

Everted Lower Lip Everted lower lip vermilion HP:0000232

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"tented upper lip, and thick or everted lower lip with coarsening of the facial features over time"

GeneReviews describes the thick/everted lower lip as part of the facial gestalt.

Ambiguous Genitalia VERY_FREQUENT Ambiguous genitalia HP:0000062

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia"

GeneReviews describes the spectrum of genital anomalies, including ambiguous genitalia.

Alpha-Thalassemia with HbH Hemoglobin FREQUENT HbH hemoglobin HP:0011903

Show evidence (2 references)

PMID:20301622 SUPPORT Human Clinical

"Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."

GeneReviews reports alpha-thalassemia in ~75% of affected individuals, supporting both the phenotype and a FREQUENT frequency band.

PMID:7697714 SUPPORT Human Clinical

"The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia."

Foundational clinical description listing alpha-thalassemia as a core component of the syndrome.

Abnormal CNS Myelination Abnormal myelination HP:0012447

Show evidence (1 reference)

PMID:37925436 SUPPORT Model Organism

"Myelination is compromised in ATR-X intellectual disability syndrome patients, but the causes are unknown."

Establishes that myelination is compromised in ATR-X syndrome patients, with the mechanism investigated in a mouse model.

🧬

Genetic Associations

1

ATRX pathogenic variants causing ATR-X syndrome

Gene: ATRX hgnc:886

X-linked recessive

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"The diagnosis of ATR-X syndrome is established in a proband with suggestive findings, a 46,XY karyotype, and a hemizygous pathogenic variant in ATRX identified by molecular genetic testing."

GeneReviews establishes ATRX as the causative gene with X-linked hemizygous pathogenic variants.

💊

Medical Actions

3

Supportive and Developmental Management

Action: supportive care MAXO:0000950

There is no disease-modifying therapy. Management is supportive and per standard of care: developmental/educational support for DD/ID, anti-seizure medication for seizures, and management of gastrointestinal manifestations, feeding difficulties, and excessive drooling.

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."

GeneReviews describes supportive, manifestation-directed management as the standard of care.

Surgical Correction of Genital Anomalies

Action: surgical procedure MAXO:0000004

Genital anomalies (e.g., hypospadias, undescended testicles) are managed per standard of care, which may include corrective urologic/surgical procedures.

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"

GeneReviews indicates genital anomalies are managed per standard of care, which includes surgical correction where indicated.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Because ATR-X syndrome is X-linked, genetic counseling is recommended. Carrier testing for at-risk females, prenatal testing, and preimplantation genetic testing are possible once the familial ATRX variant is known.

Show evidence (1 reference)

PMID:20301622 SUPPORT Human Clinical

"Once the ATRX pathogenic variant in the family has been identified, carrier testing for at-risk females, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."

GeneReviews supports genetic counseling and family-based testing options.

{ }

Source YAML

click to show

name: Alpha-thalassemia X-linked intellectual disability syndrome
creation_date: "2026-06-03T00:00:00Z"
description: >-
  Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is an
  X-linked recessive disorder caused by loss-of-function mutations in the ATRX gene,
  which encodes a chromatin-remodeling ATPase that, with DAXX, deposits histone
  variant H3.3 at heterochromatin. Affected males show severe intellectual
  disability, characteristic facial features, genital abnormalities, and a mild
  form of alpha-thalassemia (HbH inclusions), reflecting widespread dysregulation of
  gene expression at repetitive and heterochromatic loci.
category: Mendelian
parents:
- Genetic Disease
- Nervous System Disease
disease_term:
  preferred_term: ATR-X syndrome
  term:
    id: MONDO:0010519
    label: alpha thalassemia-X-linked intellectual disability syndrome
references:
- reference: PMID:20301622
  title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
  tags:
  - GeneReviews

pathophysiology:
- name: ATRX Chromatin Remodeler Loss of Function
  description: >
    ATR-X syndrome is caused by hemizygous loss-of-function variants in ATRX
    (Xq21.1), which encodes a member of the SWI2/SNF2 family of ATP-dependent
    chromatin-remodeling proteins. ATRX carries an ADD (ATRX-DNMT3-DNMT3L)
    plant-homeodomain-like zinc finger that reads the H3K9me3 heterochromatin
    mark and a SNF2-type helicase/ATPase domain. Diverse missense and truncating
    mutations disrupt either chromatin targeting or remodeling activity, leading
    to a "global transcriptional regulator" defect that dysregulates many genes,
    including the alpha-globin genes, which explains the multisystem ATR-X
    phenotype.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DECREASED
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:7697714
    reference_title: "Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have shown that ATR-X results from diverse mutations of XH2, a member of a subgroup of the helicase superfamily that includes proteins involved in a wide range of cellular functions, including DNA recombination and repair (RAD16, RAD54, and ERCC6) and regulation of transcription (SW12/SNF2, MOT1, and brahma)."
    explanation: >
      The original Gibbons et al. report identified ATRX (XH2) as a SWI2/SNF2-family
      helicase whose mutation causes ATR-X syndrome, establishing the chromatin-
      regulation defect.
  - reference: PMID:7697714
    reference_title: "Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator."
    explanation: >
      Directly supports the model that loss of ATRX function dysregulates many
      genes, including alpha-globin, producing the multisystem phenotype.
  downstream:
  - target: ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin
    causal_link_type: DIRECT
    description: >
      Loss of ATRX chromatin-remodeling function destabilizes the ATRX-DAXX
      complex and impairs H3.3 deposition at heterochromatic regions.
  - target: Tandem-Repeat Binding and Allele-Specific Gene Dysregulation
    causal_link_type: DIRECT
    description: >
      Loss of ATRX disrupts its binding to G-rich tandem repeats, causing
      allele-specific gene dysregulation including alpha-globin downregulation.
  - target: Impaired Sertoli Cell Survival and Androgen Signaling
    causal_link_type: DIRECT
    description: >
      ATRX loss in the Sertoli cell lineage causes cell-cycle arrest,
      apoptosis, and impaired androgen receptor co-activation.
  - target: Impaired Oligodendrocyte Differentiation and CNS Myelination
    causal_link_type: DIRECT
    description: >
      ATRX loss impairs oligodendrocyte progenitor differentiation along the
      oligodendrocyte lineage, producing CNS myelination deficits.
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Distinctive Craniofacial Features
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Telecanthus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Everted Lower Lip
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Feeding Difficulties
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Drooling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Skeletal Anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Gastrointestinal Anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES

- name: ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin
  description: >
    ATRX partners with the histone chaperone DAXX to deposit the
    replication-independent histone variant H3.3 at heterochromatic and
    repetitive genomic regions (pericentromeric heterochromatin, telomeres,
    and tandem repeats), maintaining the H3K9me3 silencing mark. ATRX
    localizes to promyelocytic leukemia (PML) nuclear bodies as part of this
    complex. Loss of ATRX destabilizes the ATRX-DAXX complex and impairs
    heterochromatin maintenance and proper silencing of repetitive elements.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: heterochromatin organization
    term:
      id: GO:0070828
      label: heterochromatin organization
    modifier: DECREASED
  - preferred_term: nucleosome assembly
    term:
      id: GO:0006334
      label: nucleosome assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:12953102
    reference_title: "The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Taken together, the results suggest that ATRX functions in conjunction with Daxx in a novel chromatin-remodeling complex. The defects in ATRX syndrome may result from inappropriate expression of genes controlled by this complex."
    explanation: >
      Establishes the ATRX-DAXX chromatin-remodeling complex and links its
      dysfunction to the gene-expression defects of ATR-X syndrome.
  - reference: PMID:12953102
    reference_title: "The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "a proportion of ATRX and Daxx colocalize in promyelocytic leukemia nuclear bodies, with which Daxx had previously been located"
    explanation: >
      Documents ATRX/DAXX colocalization in PML nuclear bodies, part of the
      complex's heterochromatin-associated localization.
  - reference: PMID:26773061
    reference_title: "New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We provide an overview of the individual components (ATRX, DAXX and/or H3.3) tested in each study and propose a model where the ATRX/DAXX chaperone complex deposits H3.3 to maintain the H3K9me3 modification at heterochromatin throughout the genome."
    explanation: >
      Reviews the mechanistic model that the ATRX/DAXX chaperone deposits H3.3
      to maintain the H3K9me3 heterochromatin mark genome-wide.
  - reference: PMID:28293299
    reference_title: "Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "differentially methylated regions showed evidence of preferential clustering in pericentromeric and telometric chromosomal regions, areas where ATRX has multiple functions related to maintenance of heterochromatin and genomic integrity"
    explanation: >
      A peripheral-blood DNA methylation epi-signature in ATR-X patients shows
      differential methylation clustered at pericentromeric and telomeric
      regions, consistent with ATRX's role in heterochromatin maintenance.
  downstream:
  - target: Tandem-Repeat Binding and Allele-Specific Gene Dysregulation
    causal_link_type: DIRECT
    description: >
      Impaired ATRX/DAXX-mediated heterochromatin maintenance at tandem-repeat
      regions is the mechanistic bridge to allele-specific dysregulation of
      genes embedded in those repeats.

- name: Tandem-Repeat Binding and Allele-Specific Gene Dysregulation
  description: >
    ATRX binds G-rich tandem-repeat (TR) sequences in telomeres and euchromatin,
    including sequences predicted to form non-B DNA structures such as
    G-quadruplexes. When ATRX is mutated, genes associated with these TRs are
    dysregulated in a size-dependent manner, producing skewed allelic
    expression. This mechanism accounts for the variable phenotypes seen with
    identical ATRX mutations and the down-regulation of alpha-globin, which is
    embedded in a TR-rich subtelomeric region.
  cell_types:
  - preferred_term: erythroid lineage cell
    term:
      id: CL:0000764
      label: erythroid lineage cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21029860
    reference_title: "ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression."
    explanation: >
      Demonstrates ATRX binding to tandem-repeat sequences and size-dependent
      dysregulation of associated genes when ATRX is mutated.
  - reference: PMID:21029860
    reference_title: "ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro, suggesting a mechanism by which ATRX may play a role in various nuclear processes and how this is perturbed when ATRX is mutated."
    explanation: >
      Supports the G-quadruplex/non-B DNA binding mechanism underlying ATRX's
      role at repetitive regions and its perturbation in disease.
  downstream:
  - target: Alpha-Thalassemia with HbH Hemoglobin
    causal_link_type: DIRECT

- name: Impaired Sertoli Cell Survival and Androgen Signaling
  description: >
    ATRX is required in the supporting (Sertoli) cell lineage of the developing
    testis. In a Sertoli-cell-specific Atrx knockout mouse, proliferating
    Sertoli cells undergo a prolonged G2/M phase and apoptosis during fetal
    life, producing small testes and spermatogenesis defects. ATRX physically
    interacts with the androgen receptor (AR) and co-activates AR target genes,
    providing a tissue-specific mechanism for the genital and urogenital
    anomalies (hypospadias, undescended testes, ambiguous genitalia) of ATR-X
    syndrome.
  cell_types:
  - preferred_term: Sertoli cell
    term:
      id: CL:0000216
      label: Sertoli cell
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21427128
    reference_title: "Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "ScAtrxKO mice developed small testes and discontinuous tubules, due to prolonged G2/M phase and apoptosis of proliferating Sertoli cells during fetal life."
    explanation: >
      Mouse model shows that Sertoli-cell-specific Atrx loss causes the cellular
      basis (cell-cycle arrest and apoptosis) for testicular hypoplasia.
  - reference: PMID:21427128
    reference_title: "Defective survival of proliferating Sertoli cells and androgen receptor function in a mouse model of the ATR-X syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These data suggest that ATRX can directly enhance the expression of androgen-dependent genes through physical interaction with AR."
    explanation: >
      Links ATRX to androgen-receptor-dependent transcription, a mechanism for
      the genital/urogenital anomalies seen in ATR-X syndrome.
  downstream:
  - target: Ambiguous Genitalia
    causal_link_type: DIRECT
  - target: Hypospadias
    causal_link_type: DIRECT
  - target: Cryptorchidism
    causal_link_type: DIRECT

- name: Impaired Oligodendrocyte Differentiation and CNS Myelination
  description: >
    ATRX promotes oligodendrocyte progenitor cell (OPC) differentiation along
    the oligodendrocyte lineage and suppresses astrogliogenesis. In male mice,
    loss of ATRX causes CNS myelination deficits, with OPCs failing to
    differentiate and instead acquiring a more plastic state favoring astrocytic
    differentiation. ATRX also acts systemically via thyroxine to regulate the
    onset of myelination. These functions provide a mechanism for the white
    matter pathology observed in ATR-X syndrome patients.
  cell_types:
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: DECREASED
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:37925436
    reference_title: "Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We show that loss of ATRX leads to myelination deficits in male mice that are partially rectified upon systemic thyroxine administration."
    explanation: >
      Mouse model demonstrates that ATRX loss causes CNS myelination deficits,
      providing a mechanism for white matter pathology in ATR-X syndrome.
  - reference: PMID:37925436
    reference_title: "Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "OPCs lacking ATRX fail to differentiate along the oligodendrocyte lineage and acquire a more plastic state that favors astrocytic differentiation in vitro and in vivo."
    explanation: >
      Demonstrates the OPC-intrinsic role of ATRX in promoting oligodendrocyte
      differentiation and suppressing astrogliogenesis.
  downstream:
  - target: Abnormal CNS Myelination
    causal_link_type: DIRECT

phenotypes:
- category: Phenotypic
  name: Intellectual Disability
  description: >
    Mild-to-profound developmental delay / intellectual disability is a defining
    feature of ATR-X syndrome in affected males.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay / intellectual disability (DD/ID)."
    explanation: >
      GeneReviews lists intellectual disability as a core characteristic of the
      syndrome.

- category: Phenotypic
  name: Global Developmental Delay
  description: >
    Affected males show mild-to-profound developmental delay affecting motor and
    cognitive milestones.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mild-to-profound developmental delay / intellectual disability (DD/ID)"
    explanation: >
      GeneReviews documents developmental delay as a defining feature.

- category: Phenotypic
  name: Hypotonia
  description: >
    Generalized hypotonia is a consistent feature of ATR-X syndrome.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is characterized by distinctive craniofacial features, genital anomalies, hypotonia, and mild-to-profound developmental delay"
    explanation: >
      GeneReviews lists hypotonia among the characterizing features.

- category: Phenotypic
  name: Distinctive Craniofacial Features
  description: >
    A recognizable facial gestalt with telecanthus/widely spaced eyes, a short
    triangular nose, tented upper lip, and thick or everted lower lip, which
    coarsens over time.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Distinctive craniofacial features
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short triangular nose, tented upper lip, and thick or everted lower lip with coarsening of the facial features over time."
    explanation: >
      GeneReviews details the characteristic craniofacial features of ATR-X
      syndrome.

- category: Phenotypic
  name: Telecanthus
  description: >
    Increased distance between the inner canthi (telecanthus / widely spaced
    eyes) is part of the characteristic facial appearance.
  phenotype_term:
    preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "telecanthus or widely spaced eyes, short triangular nose, tented upper lip"
    explanation: >
      GeneReviews lists telecanthus as a craniofacial feature.

- category: Phenotypic
  name: Everted Lower Lip
  description: >
    A thick or everted lower lip vermilion is a recognizable facial feature.
  phenotype_term:
    preferred_term: Everted lower lip vermilion
    term:
      id: HP:0000232
      label: Everted lower lip vermilion
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "tented upper lip, and thick or everted lower lip with coarsening of the facial features over time"
    explanation: >
      GeneReviews describes the thick/everted lower lip as part of the facial
      gestalt.

- category: Phenotypic
  name: Microcephaly
  description: >
    Small head circumference (microcephaly) is part of the craniofacial
    presentation.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial abnormalities include small head circumference"
    explanation: >
      GeneReviews documents small head circumference (microcephaly) among the
      craniofacial abnormalities.

- category: Phenotypic
  name: Ambiguous Genitalia
  description: >
    Genital anomalies in 46,XY males span a spectrum that, at its severe end,
    includes ambiguous genitalia and normal-appearing female external genitalia
    (with hypospadias and cryptorchidism captured as separate phenotypes).
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ambiguous genitalia
    term:
      id: HP:0000062
      label: Ambiguous genitalia
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genital anomalies comprise a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia, to normal-appearing female external genitalia"
    explanation: >
      GeneReviews describes the spectrum of genital anomalies, including
      ambiguous genitalia.

- category: Phenotypic
  name: Hypospadias
  description: >
    Hypospadias is a common urogenital manifestation in affected males.
  phenotype_term:
    preferred_term: Hypospadias
    term:
      id: HP:0000047
      label: Hypospadias
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a range from hypospadias and undescended testicles, to severe hypospadias and ambiguous genitalia"
    explanation: >
      GeneReviews lists hypospadias as a genital anomaly in ATR-X syndrome.

- category: Phenotypic
  name: Cryptorchidism
  description: >
    Undescended testicles (cryptorchidism) occur within the spectrum of genital
    anomalies.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a range from hypospadias and undescended testicles"
    explanation: >
      GeneReviews documents undescended testicles among genital anomalies.

- category: Phenotypic
  name: Alpha-Thalassemia with HbH Hemoglobin
  description: >
    A mild alpha-thalassemia, observed in about 75% of affected individuals, is
    a hallmark of ATR-X syndrome and reflects ATRX-dependent down-regulation of
    alpha-globin expression. It is detectable as HbH (beta4) inclusions in red
    cells and typically does not require treatment.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: HbH hemoglobin
    term:
      id: HP:0011903
      label: HbH hemoglobin
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-thalassemia, observed in about 75% of affected individuals, is mild and typically does not require treatment."
    explanation: >
      GeneReviews reports alpha-thalassemia in ~75% of affected individuals,
      supporting both the phenotype and a FREQUENT frequency band.
  - reference: PMID:7697714
    reference_title: "Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia."
    explanation: >
      Foundational clinical description listing alpha-thalassemia as a core
      component of the syndrome.

- category: Phenotypic
  name: Seizures
  description: >
    Seizures occur in a subset of affected individuals and are managed per
    standard of care.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
    explanation: >
      GeneReviews lists seizures among the manifestations requiring management.

- category: Phenotypic
  name: Feeding Difficulties
  description: >
    Gastrointestinal manifestations and feeding difficulties are common and
    require management.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "gastrointestinal manifestations and feeding difficulties, excessive drooling"
    explanation: >
      GeneReviews documents gastrointestinal manifestations and feeding
      difficulties.

- category: Phenotypic
  name: Drooling
  description: >
    Excessive drooling is a recognized manifestation requiring management.
  phenotype_term:
    preferred_term: Drooling
    term:
      id: HP:0002307
      label: Drooling
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"
    explanation: >
      GeneReviews lists excessive drooling among manifestations to manage.

- category: Phenotypic
  name: Abnormal CNS Myelination
  description: >
    Myelination is compromised in ATR-X syndrome patients. Mouse studies link
    ATRX loss to oligodendrocyte progenitor differentiation defects, providing a
    mechanism for the white matter pathology observed in patients.
  phenotype_term:
    preferred_term: Abnormal myelination
    term:
      id: HP:0012447
      label: Abnormal myelination
  evidence:
  - reference: PMID:37925436
    reference_title: "Systemic and intrinsic functions of ATRX in glial cell fate and CNS myelination in male mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Myelination is compromised in ATR-X intellectual disability syndrome patients, but the causes are unknown."
    explanation: >
      Establishes that myelination is compromised in ATR-X syndrome patients,
      with the mechanism investigated in a mouse model.

- category: Phenotypic
  name: Skeletal Anomalies
  description: >
    Skeletal abnormalities (e.g., limb anomalies, scoliosis/kyphosis) are
    characteristic features of the ATR-X syndrome phenotype.
  phenotype_term:
    preferred_term: Skeletal anomalies
    term:
      id: HP:0000924
      label: Abnormality of the skeletal system
  evidence:
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A typical phenotype is well defined, with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features."
    explanation: >
      Cohort study lists skeletal anomalies among the characteristic features of
      ATR-X syndrome.

- category: Phenotypic
  name: Gastrointestinal Anomalies
  description: >
    Gastrointestinal anomalies, including dysmotility, constipation, and
    gastroesophageal reflux, are characteristic features and a common source of
    morbidity in ATR-X syndrome.
  phenotype_term:
    preferred_term: Gastrointestinal anomalies
    term:
      id: HP:0011024
      label: Abnormality of the gastrointestinal tract
  evidence:
  - reference: PMID:36292677
    reference_title: "Phenotypic Spectrum and Molecular Findings in 17 ATR-X Syndrome Italian Patients: Some New Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with cognitive impairment, characteristic facial dysmorphism, hypotonia, gastrointestinal, skeletal, urogenital, and hematological anomalies as characteristic features"
    explanation: >
      Cohort study lists gastrointestinal anomalies among the characteristic
      features of ATR-X syndrome, consistent with the GeneReviews note on GI
      manifestations.

discussions:
- discussion_id: gap_atrx_osteosarcoma_tumor_predisposition
  prompt: >-
    Does germline ATRX loss-of-function confer a clinically meaningful tumor
    predisposition (e.g., osteosarcoma) in ATR-X syndrome, and if so, through
    which mechanism (ALT/telomere instability, heterochromatin/genome-integrity
    failure, or a sporadic association)?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#ATRX/DAXX-Mediated H3.3 Deposition at Heterochromatin
  rationale: >-
    Somatic ATRX loss is a recurrent driver of the alternative lengthening of
    telomeres (ALT) phenotype across multiple cancers, and GeneReviews notes
    that osteosarcoma has been reported in a few males with germline ATRX
    pathogenic variants. It remains unclear whether germline ATRX loss-of-
    function meaningfully predisposes to osteosarcoma or other tumors in ATR-X
    syndrome, and whether any such risk is mediated by the same heterochromatin/
    genome-integrity functions captured by the ATRX/DAXX node. The entry does
    not assert a tumor-predisposition phenotype because the association is rare
    and the germline mechanism is unestablished.
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteosarcoma has been reported in"
    explanation: >
      GeneReviews documents that osteosarcoma has been reported in a few males
      with germline ATRX pathogenic variants, motivating this open question
      about tumor predisposition in ATR-X syndrome.

genetic:
- name: ATRX pathogenic variants causing ATR-X syndrome
  notes: >
    ATR-X syndrome is caused by hemizygous pathogenic variants in ATRX (Xq21.1),
    encoding a SWI2/SNF2-family ATP-dependent chromatin-remodeling protein.
    Inheritance is X-linked; affected males have a normal 46,XY karyotype, and
    carrier females are usually unaffected. Variants are diverse missense and
    truncating changes.
  gene_term:
    preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  inheritance:
  - name: X-linked recessive
    evidence:
    - reference: PMID:20301622
      reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ATR-X syndrome is inherited in an X-linked manner."
      explanation: >
        Confirms the X-linked inheritance pattern.
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ATR-X syndrome is established in a proband with suggestive findings, a 46,XY karyotype, and a hemizygous pathogenic variant in ATRX identified by molecular genetic testing."
    explanation: >
      GeneReviews establishes ATRX as the causative gene with X-linked
      hemizygous pathogenic variants.

treatments:
- name: Supportive and Developmental Management
  description: >
    There is no disease-modifying therapy. Management is supportive and per
    standard of care: developmental/educational support for DD/ID, anti-seizure
    medication for seizures, and management of gastrointestinal manifestations,
    feeding difficulties, and excessive drooling.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: DD/ID, seizures, gastrointestinal manifestations and feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care."
    explanation: >
      GeneReviews describes supportive, manifestation-directed management as the
      standard of care.

- name: Surgical Correction of Genital Anomalies
  description: >
    Genital anomalies (e.g., hypospadias, undescended testicles) are managed per
    standard of care, which may include corrective urologic/surgical procedures.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "feeding difficulties, excessive drooling, and genital anomalies are managed per standard of care"
    explanation: >
      GeneReviews indicates genital anomalies are managed per standard of care,
      which includes surgical correction where indicated.

- name: Genetic Counseling
  description: >
    Because ATR-X syndrome is X-linked, genetic counseling is recommended.
    Carrier testing for at-risk females, prenatal testing, and preimplantation
    genetic testing are possible once the familial ATRX variant is known.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301622
    reference_title: "Alpha-Thalassemia X-Linked Intellectual Disability Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the ATRX pathogenic variant in the family has been identified, carrier testing for at-risk females, prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible."
    explanation: >-
      GeneReviews supports genetic counseling and family-based testing options.

📚

References & Deep Research

References

1

PMID:20301622

Alpha-Thalassemia X-Linked Intellectual Disability Syndrome.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

ATR-X Syndrome (Alpha-thalassemia X-linked intellectual disability syndrome): Disease Characteristics Research Report

Edison Scientific Literature 29 citations 2026-06-03T22:41:28.064931

ATR-X Syndrome (Alpha-thalassemia X-linked intellectual disability syndrome): Disease Characteristics Research Report

1. Disease Information

Overview (what is the disease?)

ATR-X syndrome is a rare, X-linked, congenital/neurodevelopmental disorder caused by hypomorphic pathogenic variants in ATRX, encoding a chromatin-remodeling ATPase. Core manifestations include moderate-to-severe intellectual/developmental disability, characteristic facial dysmorphism, hypotonia, frequent genital anomalies, and variably α-thalassemia/HbH inclusions (often mild). (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2, lupu2024pyridostigmineasa pages 1-2)

Direct abstract quote (2023 mouse-model paper summarizing the human syndrome): “Hypomorphic mutations in the X-linked ATRX gene cause a rare form of intellectual disability combined with alpha-thalassemia called ATR-X syndrome in hemizygous males. Patients also have facial dysmorphism, microcephaly, musculoskeletal defects and genital abnormalities.” (Tillotson et al., 2023; URL: https://doi.org/10.1101/2023.01.25.525394; publication year 2023) (tillotson2023anewmouse pages 1-4)

Key identifiers

OMIM (disease): 301040 (ATR-X syndrome) (wang2024identificationofa pages 1-2, cong2022identificationofa pages 1-2, lupu2024pyridostigmineasa pages 1-2)
OMIM (related/overlapping): 309580 (MRXHF1; X-linked intellectual disability-hypotonic facies syndrome-1; allelic ATRX disorder that may lack α-thalassemia) (wang2024identificationofa pages 1-2, cong2022identificationofa pages 1-2)
Orphanet: ORPHA:847 (reported in a 2024 review of genetic epigenetic-machinery disorders) (de Dieuleveult & Velasco, 2024; URL: https://doi.org/10.1051/medsci/2024181; publication year 2024) (aljaafreh2025ageneticallyconfirmed pages 5-6)
MONDO / MeSH / ICD-10 / ICD-11: Not available in the retrieved source set; should be added by querying MONDO/MeSH/ICD directly (gap noted).

Synonyms / alternative names

Alpha-thalassemia/mental retardation syndrome, X-linked (legacy terminology)
Alpha-thalassemia X-linked intellectual disability syndrome
ATR-X syndrome (cong2022identificationofa pages 1-2, lupu2024pyridostigmineasa pages 1-2)

Evidence provenance

Most clinical knowledge is derived from published patient reports/series and aggregated disease resources/reviews, increasingly using WES/WGS-confirmed diagnoses rather than only clinical/hematologic patterns. (wang2024identificationofa pages 2-5, timpano2020neurodevelopmentaldisorderscaused pages 1-2)

2. Etiology

Disease causal factors

Primary cause: germline pathogenic variants in ATRX (X-linked). ATRX encodes a chromatin remodeler/transcriptional regulator; mutations disrupt chromatin organization/localization and protein interactions (e.g., DAXX, EZH2, TERRA), contributing to chromosomal/genomic instability and transcriptional dysregulation. (yuan2024mutantatrxpathogenesis pages 1-2)

Direct abstract quote (2024 review): “These mutations disrupt the organization, subcellular localization, and transcriptional activity of ATRX, leading to chromosomal instability and affecting interactions with key regulatory proteins such as DAXX, EZH2, and TERRA.” (Yuan et al., 2024; URL: https://doi.org/10.3389/fmolb.2024.1434398; publication date Oct 2024) (yuan2024mutantatrxpathogenesis pages 1-2)

Risk factors

Sex: hemizygous males are most commonly affected; females often have milder manifestations due to skewed X-chromosome inactivation. (yuan2024mutantatrxpathogenesis pages 1-2, cong2022identificationofa pages 1-2)
Family history / carrier status: carrier mothers may show skewed X-inactivation; recurrence risk consistent with X-linked inheritance (and prenatal testing is discussed in recent case literature). (cong2022identificationofa pages 1-2)

Protective factors

No established genetic/environmental protective factors were identified in the retrieved sources (gap noted).

Gene–environment interactions

No ATR-X–specific gene–environment interaction data were identified in the retrieved sources (gap noted).

3. Phenotypes

Phenotypic spectrum (selected high-frequency features)

Evidence includes both cohort series and structured literature reviews:

Universal/near-universal: intellectual disability; characteristic facial gestalt/dysmorphism (100% in one summarized dataset). (cong2022identificationofa pages 9-10)
Microcephaly: ~75% in a compiled table from a 2022 case-review; 80% (12/15) in an Italian 17-patient series. (cong2022identificationofa pages 9-10, vaisfeld2022phenotypicspectrumanda pages 5-7)
Genital anomalies: ~63–67% in the 2022 table (e.g., cryptorchidism, small penis, ambiguous genitalia). (cong2022identificationofa pages 9-10)
Hypotonia: 40% neonatal hypotonia in the 2022 table; hypotonia described as common in reviews. (cong2022identificationofa pages 9-10, yuan2024mutantatrxpathogenesis pages 1-2)
Seizures/epilepsy: ~36% in the 2022 table and “approximately one third” in a 2020 review. (cong2022identificationofa pages 9-10, timpano2020neurodevelopmentaldisorderscaused pages 1-2)
Skeletal/musculoskeletal anomalies: common (kyphosis/scoliosis; hand/foot anomalies). In the Italian 17-patient series: scoliosis/kyphosis 59% and hand/foot anomalies 64.5%. (vaisfeld2022phenotypicspectrumanda pages 5-7)
Neuroimaging abnormalities: 59% (10/17) in the Italian series. (vaisfeld2022phenotypicspectrumanda pages 5-7)
Gastrointestinal (GI) complications: contribute substantially to morbidity; one 2024 case review cites 30% with GI complications (attributed to prior work) and emphasizes severe dysmotility/constipation/abdominal distension/GERD. (lupu2024pyridostigmineasa pages 1-2, lupu2024pyridostigmineasa pages 2-3)

Recent genotype–phenotype insights (2023–2024)

A 2024 BMC Pediatrics case report plus structured review of 63 patients/50 pathogenic variants reported that variant class correlates with certain features: epilepsy more frequent with frameshift/nonsense (57.14% and 55.56% respectively in their extracted dataset), and variants cluster in the ADD and helicase-like domains. (Wang et al., 2024; URL: https://doi.org/10.1186/s12887-024-05088-0; publication date Oct 2024) (wang2024identificationofa pages 2-5)

Onset, severity, progression

Onset: congenital/infancy with early global developmental delay and hypotonia. (lupu2024pyridostigmineasa pages 1-2, timpano2020neurodevelopmentaldisorderscaused pages 1-2)
Course: lifelong neurodevelopmental disorder with variable multisystem complications. (timpano2020neurodevelopmentaldisorderscaused pages 1-2)
Prenatal/perinatal observations: the Italian cohort noted decreased fetal movements and a high preterm birth rate (~1/3 reported, compared with ~7% general-population figure cited by the authors). (vaisfeld2022phenotypicspectrumanda pages 5-7)

Quality-of-life impact

Direct standardized QoL instrument data (e.g., EQ-5D, SF-36) were not identified in the retrieved sources; however, GI dysmotility, seizures, and severe communication impairment are repeatedly emphasized as drivers of morbidity and care burden. (lupu2024pyridostigmineasa pages 2-3, timpano2020neurodevelopmentaldisorderscaused pages 1-2)

Suggested HPO terms (examples)

Intellectual disability HP:0001249
Global developmental delay HP:0001263
Speech delay / expressive language impairment HP:0000750 (or HP:0002463)
Hypotonia HP:0001252
Microcephaly HP:0000252
Seizures HP:0001250
Cryptorchidism HP:0000028
Abnormality of genitalia HP:0000811
Constipation HP:0002019; Gastroesophageal reflux HP:0002020
Scoliosis HP:0002650
Obstructive sleep apnea HP:0002870

4. Genetic / Molecular Information

Causal gene

ATRX (OMIM *300032), Xq21.1/Xq13–q21 region (reported variably across articles); gene spans ~280 kb with 35 exons encoding a 2,492-aa protein. (tillotson2023anewmouse pages 1-4, cong2022identificationofa pages 1-2)

Pathogenic variant classes and functional consequences

Disease alleles are typically hypomorphic (partial loss of function) rather than complete null; complete Atrx loss is embryonic lethal in mice. (tillotson2023anewmouse pages 1-4)
Variant classes include missense (most common), frameshift, nonsense, and splice-altering variants. (wang2024identificationofa pages 2-5, tillotson2023anewmouse pages 1-4)
Variants cluster in key functional regions: N-terminal ADD domain (chromatin binding) and C-terminal helicase/ATPase domain. (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)

Example (2024): novel frameshift c.399_400dup (p.Leu134Cysfs*2) classified as likely pathogenic per ACMG (PVS1 + PM2-supporting) in an ATRX-related MRXHF1 case. (Wang et al., 2024; URL: https://doi.org/10.1186/s12887-024-05088-0; Oct 2024) (wang2024identificationofa pages 2-5)

Modifier genes

No validated modifier genes for clinical variability were identified in the retrieved sources (gap noted).

Epigenetic information

Peripheral-blood DNA methylation profiling can detect a characteristic ATR-X episignature, consistent with ATRX’s role in heterochromatin/telomeric–pericentromeric regulation. (schenkel2017identificationofepigenetic pages 1-2)

Direct abstract quote: “We demonstrated the evidence of a unique and highly specific DNA methylation ‘epi-signature’ in the peripheral blood of ATRX patients…” (Schenkel et al., 2017; URL: https://doi.org/10.1186/s13072-017-0118-4; publication date Mar 2017) (schenkel2017identificationofepigenetic pages 1-2)

5. Environmental Information

No specific environmental or infectious causal contributors are established for ATR-X syndrome in the retrieved sources; it is primarily a monogenic disorder. (yuan2024mutantatrxpathogenesis pages 1-2)

6. Mechanism / Pathophysiology

Current mechanistic understanding (high level)

ATRX is a chromatin remodeling factor that participates in transcriptional regulation and genome stability/heterochromatin maintenance; pathogenic variants lead to dysregulated chromatin states and downstream transcriptional programs that impact neurodevelopment and other systems (hematopoietic, skeletal, urogenital, GI). (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)

Recent developments (prioritize 2023–2024)

CNS myelination mechanism (mouse): Loss of ATRX in male mice caused myelination deficits; thyroxine partially rectified deficits, and ATRX was shown to promote oligodendrocyte progenitor (OPC) differentiation and suppress astrogliogenesis. (Rowland et al., 2023; URL: https://doi.org/10.1038/s41467-023-42752-y; publication date Nov 2023) (vaisfeld2022phenotypicspectrumanda pages 5-7)

Mechanistic causal chain (example synthesis)

1) ATRX hypomorphic variant → 2) impaired chromatin remodeling/heterochromatin maintenance and altered interactions (e.g., DAXX/EZH2/TERRA) → 3) altered transcriptional programs and genomic stability → 4) neurodevelopmental impairment (ID, microcephaly), plus multisystem anomalies (urogenital development, GI dysmotility, skeletal phenotypes) and variable α-globin dysregulation causing α-thalassemia. (yuan2024mutantatrxpathogenesis pages 1-2, tillotson2023anewmouse pages 1-4, lupu2024pyridostigmineasa pages 1-2)

Suggested ontology terms

GO (Biological Process) suggestions: * Chromatin remodeling GO:0006338 * Regulation of transcription, DNA-templated GO:0006355 * DNA repair GO:0006281 * Oligodendrocyte differentiation GO:0048709 (for myelination mechanism)

CL (Cell Ontology) suggestions: * Oligodendrocyte progenitor cell CL:0002453 * Oligodendrocyte CL:0000128 * Neuron CL:0000540

7. Anatomical Structures Affected

Organ/system level

Central nervous system (neurodevelopmental disability; neuroimaging abnormalities). (vaisfeld2022phenotypicspectrumanda pages 5-7, timpano2020neurodevelopmentaldisorderscaused pages 1-2)
Hematopoietic system (α-thalassemia/HbH inclusions in many patients). (tillotson2023anewmouse pages 1-4, lupu2024pyridostigmineasa pages 1-2)
Urogenital system (genital anomalies, cryptorchidism). (cong2022identificationofa pages 9-10, lupu2024pyridostigmineasa pages 1-2)
Gastrointestinal tract (dysmotility, constipation, GERD, abdominal distension; occasional malrotation/volvulus-like presentations). (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)
Musculoskeletal system (scoliosis/kyphosis; limb anomalies). (vaisfeld2022phenotypicspectrumanda pages 5-7)

Suggested UBERON terms (examples)

Brain UBERON:0000955
Spinal cord UBERON:0002240
Testis UBERON:0000473
Gastrointestinal tract UBERON:0001555

Subcellular localization

ATRX dysfunction is linked to chromatin and heterochromatin organization; relevant cellular compartment terms include nucleus and chromatin-associated subcompartments. (yuan2024mutantatrxpathogenesis pages 1-2)

8. Temporal Development

Typical onset: congenital/infantile developmental delay and hypotonia. (timpano2020neurodevelopmentaldisorderscaused pages 1-2, lupu2024pyridostigmineasa pages 1-2)
Course: chronic lifelong disability; multisystem complications may evolve over childhood (e.g., sleep apnea, dysthyroidism/osteoporosis noted in cohort data). (vaisfeld2022phenotypicspectrumanda pages 5-7)

9. Inheritance and Population

Inheritance

X-linked inheritance with predominant male phenotype; female carriers often have reduced penetrance/expressivity due to skewed X-inactivation. (yuan2024mutantatrxpathogenesis pages 1-2, cong2022identificationofa pages 1-2)

Epidemiology (statistics)

Published estimates vary: * 1/30,000–1/40,000 male newborns (Wang et al., 2024; URL: https://doi.org/10.1186/s12887-024-05088-0; Oct 2024) (wang2024identificationofa pages 1-2) * Incidence <1/100,000 live-born males and “more than 130 families and 200 affected individuals” (Lupu et al., 2024; URL: https://doi.org/10.3389/fped.2024.1460658; Dec 2024) (lupu2024pyridostigmineasa pages 1-2) * A broader rare-disease prevalence estimate <1–9 per 1,000,000 in a 2020 review (Timpano & Picketts, 2020; URL: https://doi.org/10.3389/fgene.2020.00885; Aug 2020) (timpano2020neurodevelopmentaldisorderscaused pages 1-2)

Interpretation: variability likely reflects evolving ascertainment and underdiagnosis, especially of ATRX allelic disorders without α-thalassemia. (timpano2020neurodevelopmentaldisorderscaused pages 1-2, wang2024identificationofa pages 2-5)

10. Diagnostics

Genetic testing (current practice)

First-line in many settings: WES/WGS with confirmatory Sanger sequencing and segregation analysis in parents, with ACMG/AMP variant classification. (wang2024identificationofa pages 2-5)
Splice-impact confirmation (when needed): RT-PCR demonstrating exon skipping (example: ATRX c.5786+4A>G causing exon 24 skipping). (Cong et al., 2022; URL: https://doi.org/10.3389/fped.2022.834087; Apr 2022) (cong2022identificationofa pages 1-2)
X-inactivation studies can support interpretation in carrier females (skewed XCI reported in a carrier mother). (cong2022identificationofa pages 1-2)

Epigenomics-based diagnostic support (episignature)

A clinically relevant diagnostic adjunct is the peripheral blood DNA methylation episignature: * Case-control comparison described as 18 patients vs 210 controls in the abstract, with hierarchical clustering separating ATR-X from controls and a set of highly informative loci (14–16 regions described). (Schenkel et al., 2017; URL: https://doi.org/10.1186/s13072-017-0118-4; Mar 2017) (schenkel2017identificationofepigenetic pages 1-2)

Key figure/table evidence for the episignature and loci: hierarchical clustering heatmap and locus table. (schenkel2017identificationofepigenetic media 15df1688, schenkel2017identificationofepigenetic media 9b890b99)

Differential diagnosis

The retrieved sources emphasize overlap with MRXHF1 (ATRX allelic disorder without α-thalassemia), implying that absence of α-thalassemia does not exclude ATRX-related disease and supports a genotype-first diagnostic approach. (wang2024identificationofa pages 1-2, cong2022identificationofa pages 1-2)

11. Outcome / Prognosis

Systematic survival curves and life expectancy estimates were not identified in the retrieved sources (gap noted). However, complication-related mortality is referenced: * “Aspiration is a common cause of death in early childhood.” (Lupu et al., 2024; URL: https://doi.org/10.3389/fped.2024.1460658; Dec 2024) (lupu2024pyridostigmineasa pages 1-2)

12. Treatment

Standard of care (current real-world implementation)

No established disease-modifying therapy is supported by the retrieved human clinical literature; management is multidisciplinary and supportive (developmental therapies, seizure management, feeding/GI management, urogenital evaluation). (wang2024identificationofa pages 2-5, lupu2024pyridostigmineasa pages 1-2)

GI dysmotility: pyridostigmine (recent 2024 development)

A 2024 case report plus literature review suggests pyridostigmine (acetylcholinesterase inhibitor) may improve pediatric GI dysmotility in ATR-X, particularly when first-line approaches fail. (Lupu et al., 2024; URL: https://doi.org/10.3389/fped.2024.1460658; Dec 2024) (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)

Direct abstract quote: “We report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine.” (Lupu et al., 2024) (lupu2024pyridostigmineasa pages 2-3)

Reported data highlights include a case titrating from ~1.6 mg/kg/day to ~3.2 mg/kg/day with maintenance and reported full symptom resolution after 1 year, and a statement that only nine pediatric cases were reported in the literature at the time. (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)

Translational evidence relevant to therapy

In mice, thyroxine partially rectified myelination deficits caused by ATRX loss, suggesting endocrine contributions to white matter pathology; this remains preclinical and is not established as a human therapy for ATR-X syndrome. (Rowland et al., 2023; URL: https://doi.org/10.1038/s41467-023-42752-y; Nov 2023) (vaisfeld2022phenotypicspectrumanda pages 5-7)

Suggested MAXO terms (examples)

Genetic testing MAXO:0000127 (genetic test)
Genetic counseling MAXO:0000073
Speech therapy MAXO:0000097
Occupational therapy MAXO:0000011
Antiepileptic therapy MAXO:0000504
Treatment of constipation / GI motility disorder MAXO:0000747 (supportive GI management; pyridostigmine use is off-label)

13. Prevention

Primary prevention is not applicable in the classic public-health sense for a monogenic disorder; prevention focuses on reproductive and complication prevention: * Carrier testing and genetic counseling for at-risk families; prenatal diagnosis discussed in recent genetic case literature. (cong2022identificationofa pages 1-2) * Tertiary prevention: aspiration prevention and proactive management of GI dysmotility/feeding issues may reduce morbidity. (lupu2024pyridostigmineasa pages 1-2, lupu2024pyridostigmineasa pages 2-3)

14. Other Species / Natural Disease

No naturally occurring ATR-X syndrome analogs in non-human species were identified in the retrieved sources (gap noted).

15. Model Organisms

Mouse models (2023)

A 2023 patient-variant knock-in mouse model (Atrx R246C; described as the most common patient mutation) recapitulated aspects of the human disorder including craniofacial defects, microcephaly and impaired neurological function, providing a platform for mechanistic studies and therapy testing. (Tillotson et al., 2023; URL: https://doi.org/10.1101/2023.01.25.525394; 2023) (tillotson2023anewmouse pages 1-4)

Mechanistic CNS myelination model (2023)

ATRX loss in male mice led to myelination deficits; targeted inactivation experiments implicated both systemic (thyroxine) and cell-intrinsic OPC roles. (Rowland et al., 2023; URL: https://doi.org/10.1038/s41467-023-42752-y; Nov 2023) (vaisfeld2022phenotypicspectrumanda pages 5-7)

Summary table for knowledge-base ingestion

The following structured table summarizes identifiers, key frequencies, diagnostic highlights, and management evidence.

Category	Details	Key evidence (with PMID if explicitly available in text; otherwise include DOI and year)	Notes
Disease name / identifiers	ATR-X syndrome; alpha-thalassemia X-linked intellectual disability syndrome; OMIM #301040. Related allelic/overlapping designation: MRXHF1, OMIM #309580. Orphanet identifier reported as ORPHA:847 in a 2024 review.	OMIM #301040 noted in multiple case/review sources; doi:10.3389/fped.2024.1460658 (2024); doi:10.1186/s12887-024-05088-0 (2024); doi:10.3389/fped.2022.834087 (2022); ORPHA:847 noted in doi:10.1051/medsci/2024181 (2024) (lupu2024pyridostigmineasa pages 1-2, wang2024identificationofa pages 1-2, cong2022identificationofa pages 1-2)	ICD/MeSH/MONDO identifiers were not directly available in retrieved context.
Common synonyms	Alpha-thalassemia/mental retardation syndrome, X-linked; alpha-thalassemia X-linked intellectual disability syndrome; ATR-X syndrome.	doi:10.3389/fped.2022.834087 (2022); doi:10.3389/fped.2024.1460658 (2024) (cong2022identificationofa pages 1-2, lupu2024pyridostigmineasa pages 1-2)	“Mental retardation” appears in legacy nomenclature but is outdated in current clinical usage.
Resource type	Disease information is derived mainly from aggregated disease-level resources/reviews and published patient case series/cohorts; recent reports often use WES/WGS-confirmed individual patients.	doi:10.1186/s12887-024-05088-0 (2024); doi:10.3390/genes13101792 (2022) (wang2024identificationofa pages 2-5, vaisfeld2022phenotypicspectrumanda pages 5-7)	Not primarily EHR-derived in the retrieved literature.
Inheritance / sex effect	X-linked inheritance; typically affects hemizygous males; females are often asymptomatic or milder because of skewed X-chromosome inactivation.	doi:10.3389/fmolb.2024.1434398 (2024); doi:10.3389/fped.2022.834087 (2022) (yuan2024mutantatrxpathogenesis pages 1-2, cong2022identificationofa pages 1-2)	Carrier mothers may show skewed XCI; counseling is important for family planning.
Causal gene	ATRX (OMIM *300032), located at Xq13-q21/Xq21.1; chromatin-remodeling ATPase of the SNF2 family; 35 exons; protein length 2,492 aa.	doi:10.3389/fped.2022.834087 (2022); doi:10.1101/2023.01.25.525394 (2023) (cong2022identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)	Core domains: N-terminal ADD domain and C-terminal helicase/ATPase domain.
Variant spectrum	Predominantly hypomorphic germline variants; missense most common; also frameshift, nonsense, splice-site, and small in-frame indels. Variants cluster in ADD and helicase-like domains. In one 2024 review set: 35 missense, 7 frameshift, 4 nonsense, 5 splicing variants among 63 reviewed patients/50 pathogenic variants.	doi:10.1186/s12887-024-05088-0 (2024); doi:10.1101/2023.01.25.525394 (2023) (wang2024identificationofa pages 2-5, tillotson2023anewmouse pages 1-4)	Germline disease alleles are typically partial loss-of-function rather than null.
Prevalence / incidence	Estimated prevalence ~1/30,000–1/40,000 male newborns in one 2024 source; another review cites incidence <1/100,000 live-born males; broader rare-disease estimate <1–9/1,000,000. More than 130 families and >200 affected individuals/cases have been described.	doi:10.1186/s12887-024-05088-0 (2024); doi:10.3389/fped.2024.1460658 (2024); doi:10.3389/fgene.2020.00885 (2020) (wang2024identificationofa pages 1-2, lupu2024pyridostigmineasa pages 1-2, timpano2020neurodevelopmentaldisorderscaused pages 1-2)	Estimates vary by source and likely reflect underdiagnosis, especially of mild/atypical cases.
Core phenotype	Severe-to-profound intellectual/developmental disability is the constant feature; facial dysmorphism, hypotonia, skeletal abnormalities, genital anomalies, and hematologic abnormalities are typical.	doi:10.3389/fmolb.2024.1434398 (2024); doi:10.3389/fgene.2020.00885 (2020) (yuan2024mutantatrxpathogenesis pages 1-2, timpano2020neurodevelopmentaldisorderscaused pages 1-2)	Expressive language is often markedly impaired; some patients lack alpha-thalassemia.
Alpha-thalassemia / hematology	Alpha-thalassemia or HbH inclusions occur in about 75% of affected individuals, but may be absent; severity of neurodevelopmental impairment does not correlate well with degree of alpha-thalassemia.	doi:10.3389/fped.2024.1460658 (2024); doi:10.3389/fped.2021.811812 (2022); doi:10.1101/2023.01.25.525394 (2023) (lupu2024pyridostigmineasa pages 1-2, tillotson2023anewmouse pages 1-4)	Absence of alpha-thalassemia does not exclude ATRX-related disease.
Phenotype frequencies (selected literature)	Review data cited in 2022 source: profound ID 100%, characteristic facial features 100%, microcephaly ~75%, genital abnormalities ~63–67%, neonatal hypotonia 40%, short stature 50%, gut dysmotility ~36%, seizures ~36%, renal/urinary abnormalities ~25%. Italian 17-patient cohort: microcephaly 12/15 (80%), short stature 11/17 (64.5%), hand/foot anomalies 11/17 (64.5%), scoliosis/kyphosis 10/17 (59%), neuroimaging signs 10/17 (59%), obstructive sleep apnea 4/17 (23.5%), dysthyroidism 3/17 (17.5%), osteoporosis 3/17 (17.5%).	doi:10.3389/fped.2022.834087 (2022); doi:10.3390/genes13101792 (2022) (cong2022identificationofa pages 9-10, vaisfeld2022phenotypicspectrumanda pages 5-7)	Frequencies vary by cohort composition, ascertainment, and whether mild ATRX-related cases are included.
Genotype–phenotype highlights	Frameshift/nonsense variants may show higher rates of epilepsy and congenital anomalies; ADD-domain variants are associated with more severe psychomotor/language impairment; C-terminal frameshifts may confer more urogenital defects.	doi:10.1186/s12887-024-05088-0 (2024); doi:10.3389/fped.2022.834087 (2022) (wang2024identificationofa pages 2-5, cong2022identificationofa pages 9-10)	Current reviews caution that many domain-based predictions remain imperfect and not fully prognostic.
Natural history / onset	Congenital or early-infantile onset with global developmental delay, hypotonia, feeding/GI issues, and delayed motor/language milestones; aspiration is a recognized cause of early childhood death. Prenatal decreased fetal movements and preterm birth (~1/3 in one cohort) have been reported.	doi:10.3389/fped.2024.1460658 (2024); doi:10.3390/genes13101792 (2022) (lupu2024pyridostigmineasa pages 1-2, vaisfeld2022phenotypicspectrumanda pages 5-7)	Lifelong neurodevelopmental disorder with multisystem complications.
Diagnostic genetics	Molecular confirmation relies on ATRX variant detection by WES/WGS or targeted sequencing, typically with Sanger confirmation; RT-PCR may confirm splice effects; X-inactivation studies can support interpretation in carrier females.	doi:10.3389/fped.2022.834087 (2022); doi:10.1186/s12887-024-05088-0 (2024) (cong2022identificationofa pages 1-2, wang2024identificationofa pages 2-5)	Modern NGS is expanding detection of atypical cases lacking classic hematologic features.
Epigenetic / biomarker diagnostics	Peripheral-blood DNA methylation “episignature” is highly specific for ATR-X syndrome; demonstrated in 18 patients vs 210 controls, with hierarchical clustering separating cases and controls; significant loci clustered in pericentromeric/telomeric regions.	doi:10.1186/s13072-017-0118-4 (2017) (schenkel2017identificationofepigenetic pages 1-2, schenkel2017identificationofepigenetic media 15df1688)	Useful as a supportive diagnostic biomarker, especially for variants of uncertain significance.
Management highlights	No disease-modifying standard therapy identified in retrieved clinical literature; management is supportive and multidisciplinary. Speech/occupational therapy may help some functional issues (e.g., drooling), though cognitive gains may be limited.	doi:10.1186/s12887-024-05088-0 (2024) (wang2024identificationofa pages 2-5)	Typical care includes developmental, neurologic, GI, nutrition, and urogenital management.
GI management / real-world implementation	GI complications are common and clinically important. Recent case-based evidence suggests pyridostigmine can improve pediatric GI dysmotility when first-line measures fail; reported doses varied, and one case had full symptom resolution after 1 year.	doi:10.3389/fped.2024.1460658 (2024) (lupu2024pyridostigmineasa pages 2-3, lupu2024pyridostigmineasa pages 1-2)	Evidence remains low-level (case report/literature review); optimal dosing and long-term safety are uncertain.
Mechanistic / translational development	2023 mouse work linked ATRX loss to myelination defects and oligodendrocyte progenitor differentiation; thyroxine partially rescued myelination deficits in male mice.	doi:10.1038/s41467-023-42752-y (2023) (vaisfeld2022phenotypicspectrumanda pages 5-7)	Promising mechanistic insight, but not established human therapy for ATR-X syndrome.
Clinical trials	No disease-specific interventional clinical trials were identified in the retrieved search context.	Clinical trials search in retrieved context (2024 search) (aljaafreh2025ageneticallyconfirmed pages 5-6)	Current care is largely individualized supportive management and complication prevention.

Table: This table summarizes the main identifiers, inheritance and molecular basis, prevalence estimates, phenotype frequencies, and current diagnostic and management highlights for ATR-X syndrome. It is designed as a compact evidence-backed reference for knowledge-base curation.

Notes on evidence gaps and recommendations

Standardized MONDO/MeSH/ICD mappings were not present in the retrieved sources and should be filled by direct ontology database queries.
High-quality natural history, prognosis, and treatment outcomes remain limited; the most actionable 2024 clinical development in the retrieved set is case-based evidence supporting pyridostigmine for severe GI dysmotility.
DNA methylation episignatures provide a concrete, clinically translatable diagnostic adjunct and are visually supported by the cited figure/table excerpts. (schenkel2017identificationofepigenetic pages 1-2, schenkel2017identificationofepigenetic media 15df1688, schenkel2017identificationofepigenetic media 9b890b99)

References

(tillotson2023anewmouse pages 1-4): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.
(yuan2024mutantatrxpathogenesis pages 1-2): Kejia Yuan, Yan Tang, Zexian Ding, Lei Peng, Jinghua Zeng, Huaying Wu, and Qi Yi. Mutant atrx: pathogenesis of atrx syndrome and cancer. Frontiers in Molecular Biosciences, Oct 2024. URL: https://doi.org/10.3389/fmolb.2024.1434398, doi:10.3389/fmolb.2024.1434398. This article has 7 citations.
(lupu2024pyridostigmineasa pages 1-2): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.
(wang2024identificationofa pages 1-2): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.
(cong2022identificationofa pages 1-2): Yan Cong, Jie Wu, Hao Wang, Ke Wu, Cui-Ping Huang, and Xue Yang. Identification of a hemizygous novel splicing variant in atrx gene: a case report and literature review. Frontiers in Pediatrics, Apr 2022. URL: https://doi.org/10.3389/fped.2022.834087, doi:10.3389/fped.2022.834087. This article has 3 citations.
(aljaafreh2025ageneticallyconfirmed pages 5-6): Suliman Aljaafreh, Ayman Alhwayan, Atwa Altawarh, Moath A. Altarawneh, Ruba Alhazaimeh, Abeer Abdalnabi, Eman Alquraan, Sleman Alabdallat, Sumaia Alrababah, and Maher Khader. A genetically confirmed case of atr-x syndrome without alpha-thalassemia: first case reported from jordan. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.88943, doi:10.7759/cureus.88943. This article has 0 citations.
(wang2024identificationofa pages 2-5): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.
(timpano2020neurodevelopmentaldisorderscaused pages 1-2): Sara Timpano and David J. Picketts. Neurodevelopmental disorders caused by defective chromatin remodeling: phenotypic complexity is highlighted by a review of atrx function. Frontiers in Genetics, Aug 2020. URL: https://doi.org/10.3389/fgene.2020.00885, doi:10.3389/fgene.2020.00885. This article has 33 citations and is from a peer-reviewed journal.
(cong2022identificationofa pages 9-10): Yan Cong, Jie Wu, Hao Wang, Ke Wu, Cui-Ping Huang, and Xue Yang. Identification of a hemizygous novel splicing variant in atrx gene: a case report and literature review. Frontiers in Pediatrics, Apr 2022. URL: https://doi.org/10.3389/fped.2022.834087, doi:10.3389/fped.2022.834087. This article has 3 citations.
(vaisfeld2022phenotypicspectrumanda pages 5-7): A Vaisfeld, S Taormina, A Simonati, and G Neri. Phenotypic spectrum and molecular findings in 17 atr-x syndrome italian patients: some new insights. genes 2022, 13, 1792. Unknown journal, 2022.
(lupu2024pyridostigmineasa pages 2-3): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.
(schenkel2017identificationofepigenetic pages 1-2): Laila C. Schenkel, Kristin D. Kernohan, Arran McBride, Ditta Reina, Amanda Hodge, Peter J. Ainsworth, David I. Rodenhiser, Guillaume Pare, Nathalie G. Bérubé, Cindy Skinner, Kym M. Boycott, Charles Schwartz, and Bekim Sadikovic. Identification of epigenetic signature associated with alpha thalassemia/mental retardation x-linked syndrome. Epigenetics & Chromatin, Mar 2017. URL: https://doi.org/10.1186/s13072-017-0118-4, doi:10.1186/s13072-017-0118-4. This article has 101 citations and is from a peer-reviewed journal.
(schenkel2017identificationofepigenetic media 15df1688): Laila C. Schenkel, Kristin D. Kernohan, Arran McBride, Ditta Reina, Amanda Hodge, Peter J. Ainsworth, David I. Rodenhiser, Guillaume Pare, Nathalie G. Bérubé, Cindy Skinner, Kym M. Boycott, Charles Schwartz, and Bekim Sadikovic. Identification of epigenetic signature associated with alpha thalassemia/mental retardation x-linked syndrome. Epigenetics & Chromatin, Mar 2017. URL: https://doi.org/10.1186/s13072-017-0118-4, doi:10.1186/s13072-017-0118-4. This article has 101 citations and is from a peer-reviewed journal.
(schenkel2017identificationofepigenetic media 9b890b99): Laila C. Schenkel, Kristin D. Kernohan, Arran McBride, Ditta Reina, Amanda Hodge, Peter J. Ainsworth, David I. Rodenhiser, Guillaume Pare, Nathalie G. Bérubé, Cindy Skinner, Kym M. Boycott, Charles Schwartz, and Bekim Sadikovic. Identification of epigenetic signature associated with alpha thalassemia/mental retardation x-linked syndrome. Epigenetics & Chromatin, Mar 2017. URL: https://doi.org/10.1186/s13072-017-0118-4, doi:10.1186/s13072-017-0118-4. This article has 101 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

ATR-X Syndrome (Alpha-thalassemia X-linked intellectual disability syndrome): Disease Characteristics Research Report

1. Disease Information

Overview (what is the disease?)

Key identifiers

Synonyms / alternative names

Evidence provenance

2. Etiology

Disease causal factors

Risk factors

Protective factors

Gene–environment interactions

3. Phenotypes

Phenotypic spectrum (selected high-frequency features)

Recent genotype–phenotype insights (2023–2024)

Onset, severity, progression

Quality-of-life impact

Suggested HPO terms (examples)

4. Genetic / Molecular Information

Causal gene

Pathogenic variant classes and functional consequences

Modifier genes

Epigenetic information

5. Environmental Information

6. Mechanism / Pathophysiology

Current mechanistic understanding (high level)

Recent developments (prioritize 2023–2024)

Mechanistic causal chain (example synthesis)

Suggested ontology terms

7. Anatomical Structures Affected

Organ/system level

Suggested UBERON terms (examples)

Subcellular localization

8. Temporal Development

9. Inheritance and Population

Inheritance

Epidemiology (statistics)

10. Diagnostics

Genetic testing (current practice)

Epigenomics-based diagnostic support (episignature)

Differential diagnosis

11. Outcome / Prognosis

12. Treatment

Standard of care (current real-world implementation)

GI dysmotility: pyridostigmine (recent 2024 development)

Translational evidence relevant to therapy

Suggested MAXO terms (examples)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mouse models (2023)

Mechanistic CNS myelination model (2023)

Summary table for knowledge-base ingestion

Notes on evidence gaps and recommendations

Artifacts